Investigational drug · Phase 2
MTX-474
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diffuse Cutaneous Systemic Sclerosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "MTX-474"
First trial start
2026
Apr 16, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MTX-474", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diffuse Cutaneous Systemic Sclerosis
Largest trials
Live from ClinicalTrials.gov: studies naming "MTX-474" as an intervention, largest first.
- EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Recruiting
Mediar TherapeuticsIndustry
NCT07287670 · 85 participants (planned) · Start Apr 16, 2026 · Primary completion Dec 2028
Drug: MTX-474 · For: Diffuse Cutaneous Systemic Sclerosis
Sites: Phoenix, Arizona; La Jolla, California; Loma Linda, California · 58 sites in all
Mediar TherapeuticsIndustry
NCT06535841 · 78 participants · Start Jul 10, 2024 · Primary completion Apr 24, 2025
Drug: MTX-474 · For: Healthy
Sites: Herston, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diffuse Cutaneous Systemic Sclerosis
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- QEL-005Phase 21 trial
Quell Therapeutics Limited · Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.